home / stock / apto / apto news

APTO News and Press, Aptose Biosciences Inc.

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APTO
Market: NASDAQ
Website: aptose.com
Menu
APTO APTO Quote APTO Short APTO News APTO Articles APTO Message Board
Get APTO Alerts

News, Short Squeeze, Breakout and More Instantly...
APTO - Aptose receives deficiency notice from Nasdaq

2024-07-19 17:23:30 ET More on Aptose Biosciences Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosciences Read the full article on Seeking Alpha For further...
APTO - Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...

APTO - Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...

APTO - Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...
APTO - Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...

APTO - Aptose Biosciences looks to raise $4.43M in a direct offering

2024-05-31 08:28:22 ET More on Aptose Biosciences Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosciences Read the full article on Seeking Alpha For further...

APTO - Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, to...
APTO - Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

2024-05-14 23:12:06 ET Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Conference Call May 14, 2024 05:00 PM ET Company Participants Susan Pietropaolo - MD, Corporate Communications and IR William Rice - Chairman, President and CEO Rafael Bejar - SVP and CMO ...

APTO - Aptose Biosciences GAAP EPS of -$0.73 beats by $0.09

2024-05-14 16:54:55 ET More on Aptose Biosciences Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosci...

APTO - Aptose Reports Results for the First Quarter 2024

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML ...
Next 10